Metropolis Healthcare Limited (METROPOLIS)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹571.65 ↓ 69.45% (1Y)

🎯 Key Takeaways

Metropolis Healthcare is in a growth phase driven by organic expansion, digital adoption, and lab consolidation, with management targeting 27-28% EBITDA margins over the next three years. Despite a recent 16% YoY revenue growth in Q1FY27 and sustained margin improvement, the company has experienced significant stock price declines, with a 69.
Revenue declined 7.7% QoQ to ₹323 in Q3FY25.
⚠️ The company faces a tax dispute involving a Rs 3,880 lakh demand, partially stayed by the Income Tax Department, which could impact near-term cash flo

Market Cap

₹10,965

P/E Ratio

71.8

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About METROPOLIS 📊 Interactive Charts

📖 The Story

Metropolis Healthcare is in a growth phase driven by organic expansion, digital adoption, and lab consolidation, with management targeting 27-28% EBITDA margins over the next three years. Despite a recent 16% YoY revenue growth in Q1FY27 and sustained margin improvement, the company has experienced significant stock price declines, with a 69.45% one-year return, reflecting broader market or sector-specific pressures rather than fundamental deterioration.

📰 What's Happening

In Q4 FY26, Metropolis reported 23% YoY revenue growth to ₹1,646 crores and 140 basis points of EBITDA margin expansion to 25.4%, driven by 13.7% organic growth, 7-8% patient volume increase, and 20% growth in TruHealth and Specialty segments. Management highlighted progress on digital adoption (25% of revenue), lab consolidation, and the rollout of 100 mini hubs to scale operations. The company is targeting 27-28% EBITDA margins over the next three years without near-term price hikes, relying instead on productivity gains and network expansion to sustain growth.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	283	277	309	291	331	313	350	323
Operating Profit	72	66	76	67	83	81	93	75
OPM %	24.9%	22.7%	24.3%	22.3%	24.2%	25.1%	25.7%	22.3%
Net Profit	33	29	36	27	37	38	47	31
EPS	₹6.51	₹5.62	₹6.92	₹5.30	₹7.11	₹7.41	₹9.08	₹6.11

Revenue has shown consistent YoY growth over the past four quarters, rising from ₹277 crore in Q1FY24 to ₹323 crore in Q3FY25, with operating margins stabilizing around 22-25% despite fluctuating profitability. While net profit and EPS have varied quarter-over-quarter, the trend in operating performance and margin expansion indicates improving operational efficiency, particularly from cost discipline and digital transformation initiatives emphasized by management.

🔮 Management Outlook & What's Next

Management has provided forward-looking guidance targeting 27-28% EBITDA margins over the next three years, underpinned by organic growth, digital adoption, and lab consolidation. They emphasized sustainable growth through network expansion (100 mini hubs planned), productivity improvements (14% YoY), and continued investment in TruHealth and Specialty segments. No near-term price increases are planned, but future adjustments may be considered based on market dynamics, with growth expected to remain organic and scalable.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1. The company faces a tax dispute involving a Rs 3,880 lakh demand, partially stayed by the Income Tax Department, which could impact near-term cash flows or profitability if unresolved. 2. Management has not provided specific near-term revenue or margin targets beyond long-term EBITDA guidance, leaving near-term execution risks unquantified. 3. Despite margin expansion, net profitability remains volatile quarter-over-quarter, raising concerns about sustainability amid rising operational costs or competitive pressures in the healthcare diagnostics space.

📋 Recent Filings

🧠 Analyst's Read

Metropolis Healthcare demonstrates strong operational momentum with consistent revenue growth, margin expansion, and strategic investments in digital and network capabilities, but the stock's significant underperformance and high valuation multiple suggest investor caution. Key near-term watchpoints include resolution of the tax dispute, pace of network expansion, and ability to convert digital adoption into sustainable profitability. Management's long-term margin targets are credible, but near-term execution and macroeconomic headwinds in healthcare spending remain critical variables.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on METROPOLIS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when METROPOLIS files new disclosures

Track METROPOLIS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track METROPOLIS — Free

Free account · 2 AI queries/day